TrialJournal for immunotherapy of cancer2026

DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy.

Yuanyuan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.